Quick Facts
Plain-English Summary
Kisspeptin-10 is the minimal biologically active fragment of Kisspeptin-54, a 54-amino-acid neuropeptide encoded by the KISS1 gene. It consists of the final ten amino acids of Kisspeptin-54 and retains the RF-amide motif at its C-terminus — the structural feature essential for binding and activating the GPR54 receptor (also known as KISS1R). Because a smaller peptide is faster to synthesise, easier to characterise, and simpler to administer in controlled doses, Kisspeptin-10 has become the standard research form used in human neuroendocrinology studies. Its receptor activity is functionally equivalent to the full-length Kisspeptin-54.
The compound's primary documented action is stimulation of gonadotropin-releasing hormone (GnRH) neurons in the hypothalamus, triggering a downstream cascade of luteinising hormone (LH) pulses from the pituitary and, in men, a measurable increase in circulating testosterone. This mechanism sits at the apex of the hypothalamic-pituitary-gonadal (HPG) axis — the central hormonal regulatory system governing reproductive function. This positions Kisspeptin-10 as a tool with potential relevance to hypogonadism, infertility, and the study of puberty onset.
Relative to most research peptides, the human evidence base for Kisspeptin-10 is unusually well developed. Researchers at Imperial College London — principally Waljit S. Dhillo and Channa N. Jayasena — have published multiple controlled IV infusion studies in healthy male and female volunteers, documenting dose-dependent LH pulses and testosterone elevation in men, and have explored administration timing in the context of IVF trigger protocols in women. These are genuinely peer-reviewed, published, replicable findings — a meaningful distinction from many compounds in the research peptide market.
Kisspeptin-10 has an extremely short IV half-life of approximately 25 minutes. All published human data involves IV infusion under clinical supervision. Subcutaneous use and self-administration protocols common in the research peptide community are not supported by controlled human pharmacokinetic data.
Community and vendor claims that Kisspeptin-10 is a "testosterone booster" or "fertility treatment" compress a nuanced investigational picture into unsupported therapeutic language. Published studies demonstrate acute hormonal responses under controlled infusion conditions — they do not establish clinical efficacy, long-term safety, or therapeutic benefit for any condition in the general population.
Mechanism of Action
Proposed mechanisms below are derived from in vitro and rodent studies only. No mechanistic pathway has been validated in a controlled human study.
All mechanistic data is derived from in vitro or rodent studies. Applicability of these pathways in humans is not established.
Animal Data
| Model | Finding | ICPS Status |
|---|---|---|
| Rodent HPG axis (male) | Kisspeptin-10 and Kisspeptin-54 produced equivalent LH pulses at matched doses; confirmed 10-residue C-terminal fragment as full pharmacophore for GPR54. Dhillo WS et al. 2005 ↗ | Preclinical |
| Rat puberty onset | Central Kisspeptin-10 administration advanced the timing of puberty onset in female rats; GPR54-null animals showed absent or delayed pubertal LH surge. Established kisspeptin as a key pubertal gate-keeper. Seminara SB et al. 2003 ↗ | Preclinical |
| GPR54-null mouse model | Mice lacking functional GPR54 are infertile with low gonadotropins and fail to undergo puberty — establishing the kisspeptin/GPR54 system as essential for reproductive function. Kisspeptin-10 rescues LH pulsatility in these animals. | Preclinical |
| Rodent psychosexual behaviour | Intracerebroventricular Kisspeptin-10 increased male sexual motivation and mounting frequency independently of acute testosterone elevation, consistent with direct limbic GPR54 effects. Clarkson J et al. 2007 ↗ | Preclinical |
| Sheep seasonal reproduction | Kisspeptin-10 administration restored LH pulsatility in seasonally anovulatory ewes, demonstrating GPR54 pathway accessibility across species and seasons. Supports cross-species relevance of the receptor system. | Preclinical |
No finding from this section has been replicated in a controlled human trial. Animal-to-human translation for peptides is uncertain and cannot be assumed.
Human Trials
| Trial | Population | Status | ICPS Status |
|---|---|---|---|
| Dhillo WS et al., 2005 | Healthy men, IV Kisspeptin-10 infusion, dose-escalation | — | Published |
| Jayasena CN et al., 2009 | Healthy men, repeated IV Kisspeptin-10 boluses | — | Published |
| Jayasena CN et al., 2011 — IVF | Women undergoing IVF, Kisspeptin-10 as ovulation trigger | — | Published |
| Dhillo WS et al. — Psychosexual | Healthy men, IV Kisspeptin-10 vs. placebo, crossover | — | Published |
| Hypogonadism studies | Men with hypogonadotropic hypogonadism | — | Preliminary |
| Subcutaneous / self-admin routes | — | — | No Data |
Kisspeptin-10 has no FDA, EMA, or Health Canada–approved indications and no published Phase III trial data for any condition as of 2026.
Safety & Side Effects
In published controlled IV infusion studies at Imperial College London, Kisspeptin-10 was well tolerated at doses used in research protocols. No serious adverse events were reported. Mild, transient flushing was the most common adverse effect noted. The short half-life (~25 minutes IV) limits systemic exposure duration.
Sustained or repeated HPG axis stimulation carries a theoretical risk of receptor desensitisation or downstream axis disruption. Continuous kisspeptin receptor activation can paradoxically suppress GnRH release — the same principle used in GnRH agonist therapy for sex hormone suppression. Unmonitored long-term use at non-physiological dosing intervals is unstudied.
- Transient flushing or warmth post-injection
- Mild headache in first hours of use
- Injection site irritation (subcutaneous route)
- Mood fluctuations reported in community — mechanism unknown
- No pharmacovigilance database exists for Kisspeptin-10
- Active or suspected hormone-sensitive malignancy
- Pregnancy or breastfeeding
- Existing HPG axis disorder without specialist oversight
- Concurrent use of GnRH analogues or sex hormone therapy
- Children and adolescents (puberty timing sensitivity)
Kisspeptin-10 is not approved by the FDA, EMA, or Health Canada for any medical indication. It is classified as a research compound and is not legal for human therapeutic use in most jurisdictions. Procurement and use outside of registered clinical trials carries regulatory and unknown health risks.
References
Research disclaimer. CompoundProfile publishes summaries of available scientific literature for educational purposes only. This page does not constitute medical advice and should not be interpreted as an endorsement of Kisspeptin-10 for any therapeutic use. Consult a licensed healthcare professional before considering any research compound. All evidence gradings reflect the state of published literature as of August 2026 and are assessed independently by ICPS.
Community Commentary
Selected discussion from r/Peptides · Curated for signal, not volume
What sets Kisspeptin-10 apart from almost everything else in the vial market is that Imperial College actually ran controlled IV infusion studies in humans and published them properly. Dhillo's group has been doing this rigorously for nearly 20 years. The LH pulse data is real, it's reproducible, and it was produced under conditions you can actually evaluate — not a biohacker forum thread. The problem is the community then takes "IV infusion at 0.4 nmol/kg in a clinical setting stimulated LH" and turns it into "subcutaneous kisspeptin-10 is a testosterone booster." Those are very different things.
Exactly this. The half-life issue is enormous and almost never discussed. Twenty-five minutes IV means subcutaneous bioavailability is genuinely unknown — proteases in subcutaneous tissue will hit an unprotected 10-residue peptide hard. There's zero published human PK data for the SC route. The clinical studies are valuable but they don't tell you anything about what a vendor vial does when you inject it at home.
People constantly ask whether they should use Kisspeptin-10 or Kisspeptin-54. From a receptor biology standpoint the answer is that for GPR54 activation they're identical — Kisspeptin-10 is the pharmacophore and the rest of the 54-residue sequence appears to affect plasma half-life more than receptor affinity. Where they differ practically is cost and availability, not efficacy at the target. The Imperial group chose Kisspeptin-10 precisely because it's the minimal active fragment — cleaner for dose-response analysis.
The tachyphylaxis question is something the community hand-waves past constantly. Jayasena 2009 showed that repeated subcutaneous Kisspeptin-54 dosing causes receptor desensitisation — LH response fell off substantially with repeated dosing. This is the same principle that makes continuous GnRH agonists like leuprolide suppress testosterone rather than raise it. Pulsatile delivery is everything with GPR54. You cannot assume that a daily or twice-daily injection protocol mimics the acute IV bolus from the published trials.
This is genuinely under-appreciated. The published IVF trigger protocol used a single acute dose — not a chronic protocol. The hypogonadism work used twice-weekly pulses with deliberate inter-dose intervals to avoid desensitisation. The vendors selling daily injection protocols have no basis in the literature for that approach.
From a clinical research perspective, the most scientifically interesting application remains the IVF trigger work. The Jayasena 2014 J Clin Invest paper showed Kisspeptin-10 could trigger oocyte maturation with a substantially lower OHSS risk than hCG — that's a genuine unmet clinical need with real patients at risk. It's also the only application where the translational path from human study to clinical practice is plausibly clear. The "natural testosterone booster" framing in the community is a distraction from the more interesting science.